Information Provided By:
Fly News Breaks for June 29, 2017
AGN
Jun 29, 2017 | 07:53 EDT
Cowen analyst Ken Cacciatore believes Allergan's presence in the migraine space should continue to strengthen in the near-term via continued Botox growth and in the longer-term via oral CGRP's. He believes the introduction of injectable CGRP's could actually create managed care increased utilization of Botox. Cacciatore reiterated his Buy rating and $400 price target on Allergan shares.
News For AGN From the Last 2 Days
There are no results for your query AGN